Clinical Trials Logo

RCC clinical trials

View clinical trials related to RCC.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06259552 Recruiting - Solid Tumor Clinical Trials

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

SPX-303
Start date: March 20, 2024
Phase: Phase 1
Study type: Interventional

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

NCT ID: NCT05931393 Recruiting - Clinical trials for Renal Cell Carcinoma

Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)

Start date: December 20, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the effects of a higher dose of cabozantinib or the effects of cabozantinib-nivolumab combination in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment. The study will have two parts or "cohorts". - Cohort 1: cabozantinib 80mg daily - Cohort 2: cabozantinib 40mg daily with nivolumab The cohort assignment will be determined by investigator, based on how much cabozantinib the participant is able to safely receive.

NCT ID: NCT05917106 Recruiting - Clinical trials for Renal Cell Carcinoma

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

Start date: December 26, 2022
Phase:
Study type: Observational [Patient Registry]

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

NCT ID: NCT03891485 Recruiting - Clinical trials for Metastatic Renal Cell Carcinoma

Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy

REVOLUTION
Start date: December 2016
Phase:
Study type: Observational

The project aims to identify Nivolumab predictive biomarkers in metastatic renal cancer patients through functional evaluation of peripheral Tregs and NKs. Moreover the efficacy of new CXCR4 antagonists (PCT/IB2011/000120/ EP2528936B1/ US2013/0079292A1) will be ex vivo evaluated in modulating Tregs and NKs function